Dr. Sunil Verma on the Evolution of Treatment in HER2-Positive Breast Cancer

Sunil Verma, MD

Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy.

Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the advances in HER2-positive breast cancer in recent years. Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy. He adds that another big advance within the malignancy is the inclusion of pertuzimab in treatment sequencing, which has improved progression free and overall survival for these patients.